登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 63 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 63
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
- 研究中心广东医科大学附属医院Affiliated Hospital of Guangdong Medical University湛江医院页面
- 研究中心桂林医学院附属医院Affiliated Hospital of Guilin Medical University桂林医院页面
- 研究中心河北大学附属医院Affiliated Hospital of Hebei University石家庄医院页面
- 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
- 研究中心无锡市人民医院Affiliated Wuxi People's Hospital of Nanjing Medical University无锡医院页面
- 研究中心安阳市肿瘤医院Anyang Tumor Hospital安阳医院页面
- 研究中心首都医科大学附属北京胸科医院Beijing Chest Hospital北京医院页面
- 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
- 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
- 研究中心重庆大学附属三峡医院Chongqing University Three Gorges Hospital重庆医院页面
- 研究中心福建医科大学附属第一医院First Affiliated Hospital of Fujian Medical University福州医院页面
- 研究中心广西医科大学第一附属医院First Affiliated Hospital of Guangxi Medical University南宁医院页面
- 研究中心河南科技大学第一附属医院First Affiliated Hospital of Henan University of Science and Technology洛阳医院页面
- 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
- 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
- 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
- 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
- 研究中心河南医药大学第一附属医院First Affiliated Hospital of Xinxiang Medical University新乡医院页面
- 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
- 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
- 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面
- 研究中心海南医学院附属医院/海南省人民医院Hainan General Hospital / Hainan Medical University hospitals海口医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心河南省人民医院Henan Provincial People's Hospital郑州医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心江苏省肿瘤医院Jiangsu Cancer Hospital南京医院页面
- 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
- 研究中心江西省人民医院Jiangxi Provincial People's Hospital南昌医院页面
- 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
- 研究中心兰州大学第二医院Lanzhou University Second Hospital兰州医院页面
- 研究中心南通市肿瘤医院Nantong Tumor Hospital南通医院页面
- 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
- 研究中心上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面
- 研究中心重庆医科大学附属第二医院Second Affiliated Hospital of Chongqing Medical University重庆医院页面
- 研究中心哈尔滨医科大学附属第二医院Second Affiliated Hospital of Harbin Medical University哈尔滨医院页面
- 研究中心山东第一医科大学第二附属医院Second Affiliated Hospital of Shandong First Medical University济南医院页面
- 研究中心遵义医科大学第二附属医院Second Affiliated Hospital of Zunyi Medical University遵义医院页面
- 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
- 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
- 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
- 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
- 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
- 研究中心中国医科大学附属盛京医院Shengjing Hospital of China Medical University沈阳医院页面
- 研究中心四川省人民医院Sichuan Provincial People's Hospital成都医院页面
- 研究中心陆军军医大学第一附属医院(西南医院)Southwest Hospital, Army Medical University重庆医院页面
- 研究中心中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面
- 研究中心空军军医大学唐都医院Tangdu Hospital西安医院页面
- 研究中心常州市第一人民医院Third Affiliated Hospital of Soochow University常州医院页面
- 研究中心中南大学湘雅三医院Third Xiangya Hospital长沙医院页面
- 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
- 研究中心潍坊市人民医院Weifang People's Hospital潍坊医院页面
- 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
- 研究中心首都医科大学宣武医院Xuanwu Hospital北京医院页面
- 研究中心徐州市中心医院Xuzhou Central Hospital徐州医院页面
- 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
- 研究中心武汉大学中南医院Zhongnan Hospital of Wuhan University武汉医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06300177,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Pathologically confirmed locally advanced, unresectable and / or metastatic non-small cell lung cancer (stage III b / III c / IV of american joint committee on cancer (AJCC) 8th);
入选标准第 3 条
Disease progression or toxicity after previous treatment with first-line anti-PD-1 / PD-L1 and platinum-containing chemotherapy is not tolerated.Subjects who have clear medical reasons and can not tolerate anti-PD-1 / PD-L1 therapy or platinum-containing chemotherapy;
入选标准第 5 条
History of interstitial lung disease, radiation pneumonitis, and immune-associated pneumonia previously treated with steroids, Or active non-infectious pneumonia with interstitial lung disease, radiation pneumonia, and immune-related pneumonia during the screening period, Presence of active tuberculosis, pneumoconiosis or grade 2 other type of pneumonia, or pulmonary function tests confirming severely impaired pulmonary function;
排除标准第 14 条
Age greater than or equal to 18 years old; male and female; eastern cooperative oncology group performance status (ECOG) score 0-1; expected survival period greater than or equal to 3 months;
入选标准第 2 条
Having at least one target lesion according to RECIST 1.1;
入选标准第 6 条
Human immunodeficiency virus (HIV) antibody positive, liver cirrhosis or active viral hepatitis;
排除标准第 20 条
Female subjects of childbearing age should agree that contraception must be used during the study and within 6 months after the end of the study; the serum pregnancy test is negative within 7 days before study enrollment and must be non-lactating subjects; male subjects should agree that contraception must be used during the study and within 6 months after the end of the study period.
入选标准第 8 条
Pregnant or lactating subjects;
排除标准第 28 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06300177,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntary participation in the study and sign of written informed consent after full informed consent, willing and able to comply with the study procedures and requirements specified in the protocol; Age greater than or equal to 18 years old; male and female; eastern cooperative oncology group performance status (ECOG) score 0-1; expected survival period greater than or equal to 3 months; Pathologically confirmed locally advanced, unresectable and / or metastatic non-small cell lung cancer (stage III b / III c / IV of american joint committee on cancer (AJCC) 8th); Subjects must provide adequate and qualified tumor tissue specimens (surgical resection samples or puncture / biopsy tissue samples within 2 years prior to screening) for confirmation of the KRAS G12C mutation in the central laboratory; Disease progression or toxicity after previous treatment with first-line anti-PD-1 / PD-L1 and platinum-containing chemotherapy is not tolerated.Subjects who have clear medical reasons and can not tolerate anti-PD-1 / PD-L1 therapy or platinum-containing chemotherapy; Having at least one target lesion according to RECIST 1.1; Good function of the major organs; Female subjects of childbearing age should agree that contraception must be used during the study and within 6 months after the end of the study; the serum pregnancy test is negative within 7 days before study enrollment and must be non-lactating subjects; male subjects should agree that contraception must be used during the study and within 6 months after the end of the study period.排除标准:Exclusion Criteria:
Treatment with a KRAS G12C mutation inhibitor or docetaxel at any previous time; NSCLC with mutations of other driver genes; Symptomatic or progressive aggravation of central nervous system metastasis or cancerous meningitis. Subjects with a history of brain metastasis may be considered to be selected if they are clinically stable; Patients with a previous history of epilepsy;presence of superior vena cava syndrome; Cardiovascular system meets any condition: New York Heart Association (NYHA) Heart Function Grade II and above congestive heart failure; Severe cardiac arrhythmias requiring medical treatment; Acute myocardial infarction, severe or unstable angina pectoris, coronary or peripheral artery bypass surgery within 6 months prior to enrollment; Left ventricular ejection fraction (LVEF) <50%; QT interval (QTcF) at prolonged; Hypertension that is not effectively controlled; Subjects with stroke or other severe cerebrovascular disease within 6 months before enrollment; History of deep vein thrombosis or any other serious thromboembolism within 3 months prior to enrollment; History of interstitial lung disease, radiation pneumonitis, and immune-associated pneumonia previously treated with steroids, Or active non-infectious pneumonia with interstitial lung disease, radiation pneumonia, and immune-related pneumonia during the screening period, Presence of active tuberculosis, pneumoconiosis or grade 2 other type of pneumonia, or pulmonary function tests confirming severely impaired pulmonary function; Severe bone damage due to tumor bone metastasis may occur at present or after randomization; Active or uncontrolled serious infection (≥grade 2 infection of common toxicity criteria for adverse events (CTC AE)) or fever of unknown origin > 38.5°C; The third space effusion (including pleural effusion, abdominal effusion or pericardial effusion), poor clinical control or the need for local symptomatic treatment such as puncture and drainage; Known impaired gastrointestinal (GI) function or known GI diseases that may significantly affect the absorption or metabolism of oral drugs. Toxicity of previous antitumor therapy, except alopecia, pigmentation, clinically insignificant laboratory abnormalities) has not recovered to grade 1, and peripheral nerve toxicity has not recovered to grade 2 ( CTCAE v5.0); Human immunodeficiency virus (HIV) antibody positive, liver cirrhosis or active viral hepatitis; Active syphilis; Patients with renal failure requiring hemodialysis or peritoneal dialysis; Poor diabetes control [fasting blood glucose (FBG)> 10 mmol/L]; Previous history of organ transplantation or readiness to undergo organ transplantation; Weight of <40 kg and BMI of <18.5 kg/m2, or weight loss of> 5% within 3 months before enrollment; Major surgical treatment or significant traumatic injury within 4 weeks prior to the first dose of this study; Receiving palliative radiotherapy with local lesions within 2 weeks before the first dose of this study; Pregnant or lactating subjects; With the combination of other primary malignancies Serious mental or mental illness or history of substance abuse or serious alcohol abuse; Known allergy to the investigational medicinal product or any ingredient in the formulation; Any other significant clinical abnormality or disease that the investigator considers poses a risk to subject safety or interferes with the medication and evaluation of the clinical study.
引自 ClinicalTrials.gov, NCT06300177, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06300177,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。